Low doses of exogenous IL-2 give Tregs a competitive advantage and increase Treg:Teff ratios, having beneficial effects in preclinical models of multiple sclerosis, autoimmune diabetes, systemic lupus erythematosus (SLE), and graft versus host disease (GvHD) [12]. This evidence concerns the gene IL2 and graft versus host disease.